A US partnership is hoping that rights to a new gene delivery
system will help it to develop avian transgenic technology as an
efficient and cost-effective biomanufacturing platform for the
production of human therapeutic protein...
The European Commission has given Europe a boost in the field of
structural genomics, awarding the European Molecular Biology
Laboratory (EMBL) and its partners €10 million to create a common
platform for researchers working in the...
Scotland's PPL Therapeutics, once one of the brightest stars in the
UK biotechnology universe, came to desultory end this week when the
company auctioned off most of its remaining assets for just
£169,000 (€242,000).
Applied Biosystems has introduced a system for rapidly identifying
and characterising potential antibody, diagnostic and therapeutic
candidates. The 8500 Affinity Chip Analyser can detect and measure
up to 400 antibody binding interactions...
Axon has licensed rights to Cellectricon's electroporation
technology to enhance the performance of its Axoporator products,
used to deliver DNA and other large molecules into cells.
NextGen Sciences of the UK has launched two new technologies that
it maintains have the potential to revolutionise protein research
and accelerate drug discovery.
Merck KGaA buys ProteoPlex in a move designed to shore up its
position in the emerging microarray market, estimated to reach $2
billion (€1.76bn) in 2008.
Scientists have developed a way of making proteins in sugarcane
that they claim will be safe and less expensive than transgenic
approaches using animals.
Invitrogen has made a cash offer for fellow US company Molecular
Probes in a deal which would give the firm a very strong presence
in fluorescence reagents for use in labelling molecules for
biological research and drug discovery.
The prospect of using chicken eggs as commercial 'biofactories' for
the production of protein-based drugs has moved a step closer with
the announcement of a study showing that transgenic cockerels can
pass on an introduced...
Large Scale Biology Corporation (LSBC) has started a research
collaboration with Novozymes Biotech to apply LSBC's gene shuffling
and molecular evolution technologies to genes of interest to
Novozymes Biotech.
Genetronics Biomedical has completed the sale its BTX division to
Harvard Bioscience for $3.7 million. Genetronics Biomedical's
stockholders approved the sale in a meeting on Friday.
